



# RESEARCH REPORT



**SMART IN VITRO DIAGNOSTICS**  
ARTIFICIAL INTELLIGENCE FOR IVD MARKETS BY APPLICATION, BY  
TECHNOLOGY AND BY USER  
WITH EXECUTIVE AND CONSULTANT GUIDES  
2025 - 2029





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

## Table of Contents

1	Market Guides .....	20
1.1	Strategic Situation Analysis .....	21
1.2	Guide for Executives, Marketing, and Business Development Staff.....	25
1.3	Guide for Management Consultants and Investment Advisors.....	26
2	Introduction and Market Definition .....	27
2.1	What are Smart Diagnostics? .....	28
2.2	Market Definition .....	30
2.2.1	Revenue Market Size.....	30
2.3	Methodology.....	32
2.3.1	Methodology.....	32
2.3.2	Sources.....	32
2.3.3	Authors .....	32
2.4	Perspective: Healthcare and the IVD Industry .....	34
2.4.1	Global Healthcare Spending .....	34
2.4.2	Spending on Diagnostics .....	35
2.4.3	Important Role of Insurance for Diagnostics .....	37
3	Market Overview.....	38
3.1	Players in a Dynamic Market.....	39
3.1.1	Academic Research Lab .....	40

3.1.2 Diagnostic Test Developer.....	40
3.1.3 Instrumentation Supplier .....	41
3.1.4 Chemical/Reagent Supplier.....	41
3.1.5 Pathology Supplier .....	41
3.1.6 Independent Clinical Laboratory .....	42
3.1.7 Public National/regional Laboratory .....	42
3.1.8 Hospital Laboratory .....	43
3.1.9 Physicians Office Lab (POLS) .....	43
3.1.10 Audit Body.....	44
3.1.11 Certification Body.....	44
3.2 Understanding Artificial Intelligence.....	46
3.2.1 Artificial intelligence.....	46
3.2.2 Machine learning .....	47
3.2.3 Deep learning.....	48
3.2.4 Convolutional neural networks .....	50
3.2.5 Generative adversarial networks.....	53
3.2.6 Limitations .....	53
3.3 AI Applications in IVD.....	56
3.3.1 Infectious Disease.....	56
3.3.1.1 Known vs. Unknown.....	57
3.3.1.2 TMI.....	57
3.3.1.3 Disease surveillance .....	57
3.3.1.4 Outbreak detection .....	57
3.3.1.5 Contact tracing .....	58

3.3.1.6 Forecasting.....	58
3.3.1.7 Drug discovery .....	58
3.3.1.8 Resource allocation .....	58
3.3.2 Oncology .....	59
3.3.2.1 Electronic health records.....	59
3.3.2.2 Genomic analysis .....	59
3.3.2.3 Treatment planning .....	59
3.3.2.4 Clinical trial matching .....	60
3.3.3 Anatomic Pathology.....	60
3.3.3.1 Image analysis .....	60
3.3.3.2 Tumor segmentation .....	60
3.3.3.3 Disease classification.....	61
3.3.3.4 Predictive modeling .....	61
3.3.3.5 Quality control .....	61
3.3.3.6 Digital pathology .....	61
3.3.4 Cardiology .....	62
3.3.4.1 Electrocardiogram analysis .....	62
3.3.4.2 Electronic health records.....	62
3.3.4.3 Genomic analysis .....	62
3.3.4.4 Treatment planning .....	63
3.3.4.5 Prediction of outcomes.....	63
3.3.5 Diabetes.....	63
3.3.5.1 Diagnosis .....	63
3.3.5.2 Blood glucose monitoring .....	64

3.3.5.3	Personalized treatment plans .....	64
3.3.5.4	Medication management.....	64
3.3.5.5	Diabetes education .....	65
3.3.5.6	Predictive analytics .....	65
3.3.6	General Medicine .....	65
3.3.6.1	Diagnosis .....	65
3.3.6.2	Predictive Analytics .....	65
3.3.6.3	Personalized Treatment Plans .....	66
3.3.6.4	Medication Management.....	66
3.3.6.5	Disease Monitoring .....	66
3.3.6.6	Telemedicine.....	66
4	Market Trends .....	68
4.1	Factors Driving Growth .....	69
4.1.1	Outcome Improvement .....	69
4.1.2	The Aging Effect .....	70
4.1.3	Cost Containment.....	72
4.1.4	Physician Impact .....	72
4.1.5	Cost of Intelligence .....	73
4.2	Factors Limiting Growth .....	74
4.2.1	State of knowledge.....	74
4.2.2	Genetic Blizzard.....	75
4.2.3	Protocol Resistance.....	75
4.2.4	Regulation and coverage.....	75
4.3	Instrumentation, Automation and Diagnostic Trends .....	76

4.3.1	Traditional Automation and Centralization.....	76
4.3.2	The New Automation, Decentralization and Point Of Care .....	76
4.3.3	Instruments Key to Market Share.....	78
4.3.4	Bioinformatics Plays a Role .....	78
4.3.5	PCR Takes Command.....	79
4.3.6	Next Generation Sequencing Fuels a Revolution.....	80
4.3.7	NGS Impact on Pricing.....	81
4.3.8	Whole Genome Sequencing, A Brave New World .....	81
4.3.9	Companion Diagnostics Blurs Diagnosis and Treatment .....	81
4.3.10	Shifting Role of Diagnostics.....	83
5	Recent Developments.....	84
5.1	Recent Developments – Importance and How to Use This Section .....	85
5.1.1	Importance of These Developments .....	85
5.1.2	How to Use This Section.....	85
5.2	Ataraxis AI Launches AI Cancer Dx.....	85
5.3	Tempus Immuno-Oncology Portfolio AI-enabled.....	87
5.4	AI enables precision diagnosis of cervical cancer .....	89
5.5	UK to Rollout Digital Pathology Across NHS.....	89
5.6	AI Based Next-Generation Colorectal Cancer Test .....	90
5.7	Evident, Corista, Sakura Finetek, Visiopharm Form Digital Pathology Alliance .....	94
5.8	Viome Life Sciences Raises \$86.5M in Oversubscribed Series C Round.....	95
5.9	Becton Dickinson Gets Clearance for AI-Based Bacterial Imaging.....	96
5.10	Paige, Leica Biosystems Expand Digital Pathology Partnership .....	97
5.11	Clarapath Acquires Digital Pathology Company Crosscope .....	97

5.12	CanSense to Develop Colorectal Cancer Test .....	99
5.13	Owkin-led Machine Learning Study IDs Cancer Treatment Biomarkers .....	99
5.14	Guardant Health to Integrate Lunit's AI PD-L1 Algorithm.....	105
5.15	Vésale Bioscience to Develop AI Phage Therapy Diagnostic Platform .....	106
5.16	Caris Life Sciences To Use AI and Machine Learning.....	106
5.17	Numares Health To Develop AI for "Metabolite Constellations".....	107
5.18	Sepsis Testing Startup DeepUll to Use AI for Medical Decisions .....	108
5.19	Viome Life Sciences Raises \$67M in Series C Financing For AI Cancer Dx .....	108
5.20	ADM Diagnostics Wins Grant for Brain Injury Test Development .....	109
5.21	Paige to Develop New AI-based Pathology Test .....	110
5.22	Aiforia Gains CE-IVD Mark for AI-Powered Histopathology .....	114
5.23	Genetic Profiling May Identify Patients Who Do Not Need Radiation Therapy .....	115
5.24	Thermo Fisher Introduces Homologous Score for Cancer Profiling .....	116
5.25	Genomic Test IDs Cancer Cells Early .....	118
6	Profiles of Key Players.....	123
6.1	Adaptive Biotechnologies.....	124
6.2	Aidoc.....	126
6.3	Anumana.....	127
6.4	ARUP Laboratories.....	128
6.5	Atomwise .....	130
6.6	Bayesian Health.....	131
6.7	Behold.ai .....	132
6.8	BGI Genomics Co. Ltd .....	133
6.9	bioMérieux Diagnostics.....	135

6.10	Bio-Rad Laboratories, Inc.....	138
6.11	Cambridge Cognition .....	140
6.12	Cardiologs (Phillips) .....	142
6.13	CareDx .....	143
6.14	Caris Molecular Diagnostics .....	145
6.15	Cleerly .....	146
6.16	ClosedLoop AI .....	148
6.17	CloudMedX Health .....	149
6.18	Deepcell .....	150
6.19	Digital Diagnostics.....	151
6.20	EKF Diagnostics Holdings .....	152
6.21	Freenome.....	154
6.22	GE Healthcare .....	155
6.23	Glooko.....	156
6.24	Idoven .....	157
6.25	Illumina .....	158
6.26	Infohealth.....	159
6.27	Jade .....	160
6.28	K Health.....	161
6.29	Lunit .....	162
6.30	MaxCyte .....	163
6.31	Mayo Clinic Laboratories.....	164
6.32	Medtronic .....	165
6.33	Merative .....	167

6.34	Nanox.....	168
6.35	NIOX Group .....	169
6.36	Niramai Health Analytix .....	170
6.37	NVIDIA .....	171
6.38	Oncohost .....	174
6.39	OraLiva.....	175
6.40	Owkin .....	176
6.41	Oxford Nanopore Technologies .....	178
6.42	Pacific Biosciences.....	180
6.43	Paige.AI.....	182
6.44	PathAI.....	183
6.45	Perthera .....	184
6.46	Philips Healthcare.....	185
6.47	Prognos .....	187
6.48	Qiagen .....	188
6.49	Qure.ai .....	191
6.50	Renalytix.....	192
6.51	Seegene.....	194
6.52	Siemens Healthineers .....	196
6.53	Sophia Genetics .....	198
6.54	Sysmex.....	199
6.55	Viz.ai .....	202
7	The Global Market for Smart Diagnostics.....	203
7.1	Global Market Overview by Country .....	204

7.1.1	Table – Global Market by Country.....	204
7.1.2	Chart - Global Market by Country .....	205
7.2	Global Market by Application - Overview .....	206
7.2.1	Table – Global Market by Application .....	206
7.2.2	Chart – Global Market by Application – Base/Final Year Comparison .....	207
7.2.3	Chart – Global Market by Application – Base Year .....	208
7.2.4	Chart – Global Market by Application – Final Year.....	209
7.2.5	Chart – Global Market by Application – Share by Year.....	210
7.2.6	Chart – Global Market by Application – Segment Growth .....	211
7.3	Global Market by Technology - Overview.....	212
7.3.1	Table – Global Market by Technology .....	212
7.3.2	Chart – Global Market by Technology – Base/Final Year Comparison .....	213
7.3.3	Chart – Global Market by Technology – Base Year .....	214
7.3.4	Chart – Global Market by Technology – Final Year.....	215
7.3.5	Chart – Global Market by Technology – Share by Year.....	216
7.3.6	Chart – Global Market by Technology – Segment Growth .....	217
7.4	Global Market by Place - Overview .....	218
7.4.1	Table – Global Market by Place.....	218
7.4.2	Chart – Global Market by Place – Base/Final Year Comparison .....	219
7.4.3	Chart – Global Market by Place – Base Year.....	220
7.4.4	Chart – Global Market by Place – Final Year.....	221
7.4.5	Chart – Global Market by Place – Share by Year.....	222
7.4.6	Chart – Global Market by Place – Segment Growth .....	223
8	Global Markets – By Application.....	224

8.1	Cancer.....	225
8.1.1	Table Cancer Testing – by Country.....	225
8.1.2	Chart - Cancer Testing Growth .....	226
8.2	Infectious Disease Testing .....	227
8.2.1	Table Infectious Disease Testing – by Country .....	227
8.2.2	Chart – Infectious Disease Testing Growth .....	228
8.3	Metabolic Testing .....	229
8.3.1	Table Metabolic Testing – by Country .....	229
8.3.2	Chart - Metabolic Testing Growth.....	230
8.4	Cardiac Testing .....	231
8.4.1	Table Cardiac Testing – by Country.....	231
8.4.2	Chart - Cardiac Testing Growth.....	232
8.5	Diabetes Testing .....	233
8.5.1	Table Diabetes Testing – by Country .....	233
8.5.2	Chart - Diabetes Testing Growth.....	234
8.6	Other Disease Testing.....	235
8.6.1	Table Other Disease Testing – by Country.....	235
8.6.2	Chart – Other Disease Testing Growth.....	236
9	Global Markets – By Technology .....	237
9.1	NGS Technology.....	238
9.1.1	Table NGS Technology – by Country .....	238
9.1.2	Chart – NGS Technology Growth.....	239
9.2	PCR Technology .....	240
9.2.1	Table PCR Technology – by Country .....	240

9.2.2	Chart – PCR Technology Growth.....	241
9.3	Chemistry/IA Technology .....	242
9.3.1	Table Chemistry/IA Technology – by Country.....	242
9.3.2	Chart - Chemistry/IA Technology Growth.....	243
9.4	Pathology Technology.....	244
9.4.1	Table Pathology Technology – by Country.....	244
9.4.2	Chart - Pathology Technology Growth .....	245
9.5	Other Technology .....	246
9.5.1	Table Other Technology – by Country.....	246
9.5.2	Chart - Other Technology Growth .....	247
10	Global Markets – By Place.....	248
10.1	Research.....	249
10.1.1	Table Research – by Country .....	249
10.1.2	Chart – Research Growth .....	250
10.2	Pharmaceutical Research.....	251
10.2.1	Table Pharmaceutical Research – by Country .....	251
10.2.2	Chart - Pharmaceutical Research Growth .....	252
10.3	Clinical .....	253
10.3.1	Table Clinical – by Country .....	253
10.3.2	Chart - Clinical Growth .....	254
10.4	Other Place .....	255
10.4.1	Table Other Place – by Country .....	255
10.4.2	Chart – Other Place Growth.....	256
11	Appendices.....	257

11.1	United States Clinical Laboratory Fees Schedule .....	258
11.1.1	Laboratory Fees Schedule .....	258
11.1.2	The Most Used IVD Assays .....	382
11.1.3	The Highest Grossing Assays .....	387

## Table of Tables

Table 1 Market Players by Type .....	40
Table 2 Factors Driving Growth.....	69
Table 3 Four Factors Limiting Growth .....	74
Table 4 Seven Key Diagnostic Laboratory Technology Trends .....	76
Table 5 - Global Market by Region .....	204
Table 6 Global Market by Application .....	206
Table 7 Global Market by Technology .....	212
Table 8 Global Market by Place.....	218
Table 9 Cancer Testing by Country.....	225
Table 10 Infectious Disease Testing by Country .....	227
Table 11 Metabolic Testing by Country .....	229
Table 12 Cardiac Testing by Country.....	231
Table 13 Diabetes Testing by Country .....	233
Table 14 Other Disease Testing by Country .....	235
Table 15 NGS Technology by Country .....	238
Table 16 PCR Technology by Country .....	240
Table 17 Chemistry/IA Technology by Country.....	242
Table 18 Pathology Technology by Country .....	244
Table 19 Other Technology by Country.....	246
Table 20 Research by Country .....	249
Table 21 Pharmaceutical Research by Country .....	251

Table 22 Clinical by Country.....	253
Table 23 Other Place by Country.....	255
Table 24 Laboratory Fee Schedule .....	258
Table 25 The Most Common Assays.....	382
Table 26 Largest Revenue Assays.....	387

## Table of Figures

Figure 1 Global Healthcare Spending .....	35
Figure 2 The Lab Test Pie .....	36
Figure 3 The Road to Diagnostics .....	39
Figure 4 AI and Learning Methods .....	47
Figure 5 The Changing Age of The World's Population.....	70
Figure 6 Health Care Consumption by Age .....	71
Figure 7 Cancer Incidence - Age at Diagnosis.....	72
Figure 8 Centralized vs. Decentralized Laboratory Service .....	77
Figure 9 A Highly Multiplexed Syndromic Testing Unit.....	78
Figure 10 The Real Cost to Sequence the Human Genome.....	80
Figure 11 The Codevelopment Process .....	82
Figure 12 Comparing MDx Diagnostic and Traditional Testing.....	83
Figure 13 Base Year Country Global Share .....	205
Figure 14 Global Market by Application - Base vs. Final Year.....	207
Figure 15 Market by Application Base Year .....	208
Figure 16 Market by Application Final Year.....	209
Figure 17 Application Share by Year.....	210
Figure 18 Application Segment Growth .....	211
Figure 19 Global Market by Technology - Base vs. Final Year.....	213
Figure 20 Market by Technology Base Year .....	214
Figure 21 Market by Technology Final Year.....	215

Figure 22 Market by Technology Share by Year .....	216
Figure 23 Market by Technology Segment Growth .....	217
Figure 24 Market by Place - Base vs. Final Year .....	219
Figure 25 Market by Place Base Year .....	220
Figure 26 Market by Place Final Year.....	221
Figure 27 Market by Place Share by Year .....	222
Figure 28 Market by Place Segment Growth .....	223
Figure 29 Cancer Testing Growth.....	226
Figure 30 Infectious Disease Testing Growth.....	228
Figure 31 Metabolic Testing Growth .....	230
Figure 32 Cardiac Testing Growth.....	232
Figure 33 Diabetes Testing Growth.....	234
Figure 34 Other Disease Testing Growth .....	236
Figure 35 NGS Technology Growth .....	239
Figure 36 PCR Technology Growth .....	241
Figure 37 Chemistry/IA Technology Growth.....	243
Figure 38 Pathology Technology Growth .....	245
Figure 39 Other Technology Growth.....	247
Figure 40 Research Growth.....	250
Figure 41 Pharmaceutical Research Growth .....	252
Figure 42 Clinical Growth .....	254
Figure 43 Other Place Growth .....	256